Teva Pharmaceutical Indu... Aktie - TEV

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

14,60

Gebot

14,45

Fragen

14,70

Volumen

8.667

14,20 Tagesbereich 14,65

11,55 52-Wochen-Bereich 22,00

Marktkapitalisierung

16,554B

Handelsende

14,65

Handelsbeginn

14,65

Letzte Trade

14.65

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

12.942

Ausgegebene Aktien

1.133.838.689

Dividendenrendite

Kurs-Gewinn-Verhältnis

-10,24

Gewinn pro Aktie (EPS)

-1,45

Erlöse

16,54B

Nettogewinn

-1,64B

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.tevapharm.com

Hauptsitz

Tel Aviv, Center, Isr

Gegründet

1901

Teva Pharmaceutical Industries Ltd is listed in the Pharmaceutical Preparations sector of the Tradegate (DE) with ticker TEV. The last closing price for Teva Pharmaceutical Indu... was 14,65 €. Over the last year, Teva Pharmaceutical Indu... shares have traded in a share price range of 11,55 € to 22,00 €.

Teva Pharmaceutical Indu... currently has 1.133.838.689 shares in issue. The market capitalisation of Teva Pharmaceutical Indu... is 16,61 € billion. Teva Pharmaceutical Indu... has a price to earnings ratio (PE ratio) of -10.24.

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March TEL AVIV, Israel, March 03...

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals...

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension...

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in...

Les besoins du patient au centre de toutes les priorités : pourquoi l’Europe doit agir pour protéger l’accès aux médicaments ?

Les besoins du patient au centre de toutes les priorités : pourquoi l’Europe doit agir pour protéger l’accès aux médicaments ? AMSTERDAM, 21...

Der Patient steht an erster Stelle: Warum Europa handeln muss, um den Zugang zu Arzneimitteln zu sichern

Der Patient steht an erster Stelle: Warum Europa handeln muss, um den Zugang zu Arzneimitteln zu sichern AMSTERDAM, Feb. 21, 2025 (GLOBE...

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. In October 2024, the U.S. Food and Drug Administration...

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th...

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept...

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.35	-2.34113712375	14.95	15.15	14.2	4859	14.92493518	DE
4	-1.2	-7.59493670886	15.8	16.2	13.3	12003	14.81947735	DE
12	-6.6	-31.1320754717	21.2	21.5	13.3	12942	17.32588448	DE
26	-1.15	-7.30158730159	15.75	22	13.3	13672	17.78836379	DE
52	1.6	12.3076923077	13	22	11.55	14778	16.29629265	DE
156	5.66	63.3109619687	8.94	22	7.58	17424	13.57225176	DE
260	5.66	63.3109619687	8.94	22	7.58	17424	13.57225176	DE

TEV - Frequently Asked Questions (FAQ)

What is the current Teva Pharmaceutical Indu... share price?

The current share price of Teva Pharmaceutical Indu... is 14,60 €

How many Teva Pharmaceutical Indu... shares are in issue?

Teva Pharmaceutical Indu... has 1.133.838.689 shares in issue

What is the market cap of Teva Pharmaceutical Indu...?

The market capitalisation of Teva Pharmaceutical Indu... is EUR 16,61B

What is the 1 year trading range for Teva Pharmaceutical Indu... share price?

Teva Pharmaceutical Indu... has traded in the range of 11,55 € to 22,00 € during the past year

What is the PE ratio of Teva Pharmaceutical Indu...?

The price to earnings ratio of Teva Pharmaceutical Indu... is -10,24

What is the cash to sales ratio of Teva Pharmaceutical Indu...?

The cash to sales ratio of Teva Pharmaceutical Indu... is 1,01

What is the reporting currency for Teva Pharmaceutical Indu...?

Teva Pharmaceutical Indu... reports financial results in USD

What is the latest annual turnover for Teva Pharmaceutical Indu...?

The latest annual turnover of Teva Pharmaceutical Indu... is USD 16,54B

What is the latest annual profit for Teva Pharmaceutical Indu...?

The latest annual profit of Teva Pharmaceutical Indu... is USD -1,64B

What is the registered address of Teva Pharmaceutical Indu...?

The registered address for Teva Pharmaceutical Indu... is 124 DVORA HANEVI’A ST, TEL AVIV, CENTER, 6944020

What is the Teva Pharmaceutical Indu... website address?

The website address for Teva Pharmaceutical Indu... is www.tevapharm.com

Which industry sector does Teva Pharmaceutical Indu... operate in?

Teva Pharmaceutical Indu... operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
AMIMedondo Holding AG	0,498 € (91,54%)	110
8AW0Ocean Biomedical Inc	0,094 € (77,36%)	521,78k
51JVivoPower International PLC	3,72 € (73,83%)	45,8k
PU11Social Chain AG	0,025 € (66,67%)	23,7k
4NM1China Evergrande New Energy Vehicle Group Limited	0,0223 € (57,04%)	68,3k
EJ7Energy Resources of Australia	0,001 € (-33,33%)	1,4M
E3O1Nexoptic Technology Corp	0,006 € (-29,41%)	70,88k
PA8Paion AG	0,0196 € (-27,94%)	9,58k
K1SNKlondike Silver Corporation	0,013 € (-27,78%)	100k
CNWCodon AG	0,013 € (-25,71%)	5k
D7GNel ASA	0,226 € (-7,57%)	9,31M
DMJDynaCERT Inc	0,1275 € (10,87%)	7,11M
DMLSayona Mining Limited	0,0109 € (-5,22%)	6,63M
FMKEcograf Limited	0,253 € (8,58%)	4,53M
E3BEutelsat Communications	4,86 € (44,47%)	2,66M

Rendering Error

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Teva Pharmaceutical Industries Ltd (TEV)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Teva Pharmaceutical Industries Ltd

TEV Neueste Nachrichten

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Les besoins du patient au centre de toutes les priorités : pourquoi l’Europe doit agir pour protéger l’accès aux médicaments ?

Der Patient steht an erster Stelle: Warum Europa handeln muss, um den Zugang zu Arzneimitteln zu sichern

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

TEV - Frequently Asked Questions (FAQ)

Beweger

TEV Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Teva Pharmaceutical Industries Ltd (TEV) Börsenkurse

Teva Pharmaceutical Industries Ltd (TEV)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Teva Pharmaceutical Industries Ltd

TEV Neueste Nachrichten

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Les besoins du patient au centre de toutes les priorités : pourquoi l’Europe doit agir pour protéger l’accès aux médicaments ?

Der Patient steht an erster Stelle: Warum Europa handeln muss, um den Zugang zu Arzneimitteln zu sichern

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

TEV - Frequently Asked Questions (FAQ)

Beweger

TEV Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen